Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Nivolumab in Leiomyosarcoma
NCT04624178Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib, nivolumab in leiomyosarcoma (LMS), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2020; status: active, not recruiting.
02
Drugs
rucaparibnivolumab
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04624178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624178.